Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
BIONTECH SE has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, indicating that the current docket is distributed across separate examination assignments.
ROONEY, NORA MAUREEN is the busiest examiner, with 1 pending matter. No examiner concentration is shown in the supplied data. Counsel should manage each application against its own prosecution history while reviewing the portfolio for consistent claim terminology, disclosure positions, and opportunities to coordinate technical arguments.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
| SABOUR, GHAZAL | 1 | 34.2% | +35.0% |
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18334820 | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY | ROONEY, NORA MAUREEN | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17495571 | METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CHARACTERIZATION OF CD4+ T CELLS | SABOUR, GHAZAL | 43d overdue |
| 17599468 | COMPOSITIONS AND METHODS FOR PREPARING T CELL COMPOSITIONS AND USES THEREOF | FAUST, AMBER KATHLEEN | 2d overdue |
| 18334820 | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY | ROONEY, NORA MAUREEN | 34d |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1686 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18334820 | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY | ROONEY, NORA MAUREEN | 1641 | §102§112 | Final Rejection | 34d | Pending | Jun 14, 2023 |
| 17495571 | METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CHARACTERIZATION OF CD4+ T CELLS | SABOUR, GHAZAL | 1686 | §103§112DP | Final Rejection | 43d overdue | Pending | Oct 06, 2021 |
| 17599468 | COMPOSITIONS AND METHODS FOR PREPARING T CELL COMPOSITIONS AND USES THEREOF | FAUST, AMBER KATHLEEN | 1643 | §103§112DP | Non-Final OA | 2d overdue | Pending | Sep 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIONTECH SE has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Nora Maureen Rooney has the most, with 1 of BIONTECH SE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
